Eikonoklastes Therapeutics to advance next-generation tissue factor (TF) immunotherapies

(CincyTech) Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing. Working with The Ohio State University Corporate Engagement Office and seed investor CincyTech, the company was formed to advance technology discovered and engineered in the lab of Dr. Zhiwei Hu, MD, Ph.D., and licensed from the Ohio State Innovation Foundation.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news